{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:05:03Z","timestamp":1764828303983,"version":"3.28.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pantoprazole is an irreversible proton pump inhibitor that is administered as a racemic mixture clinically. The effects of pantoprazole sodium (PAN\u00b7Na) enantiomers on acid-related lesions were compared using models of pylorus ligation induced ulcer, histamine induced ulcer and reflux oesophagitis in rats and guinea-pigs. Compared with (+)-PAN\u00b7Na and (\u00b1)-PAN\u00b7Na, (-)-PAN\u00b7Na showed much stronger inhibitory effects on pylorus ligation induced and histamine induced ulcers, but similar effects on reflux oesophagitis. The doses of (-)-PAN\u00b7Na, (+)-PAN\u00b7Na and (\u00b1)-PAN\u00b7Na required for 50% inhibition (ID50) of acid-related lesions were 1.28, 5.03 and 3.40 mg kg\u22121 against pylorus ligation induced ulcer, 1.20, 4.28 and 3.15 mg kg\u22121 against histamine induced ulcer, and 2.92, 3.56 and 3.70 mg kg\u22121 against reflux oesophagitis, respectively. The inhibitory effects of PAN\u00b7Na enantiomers on basal gastric acid output were compared in rats with acute fistula. In contrast to inhibitory rates of 89.3% and 83.6% on gastric acid output by (-)-PAN\u00b7Na and (\u00b1)-PAN\u00b7Na at 1.5 mg kg\u22121, (+)-PAN\u00b7Na had an inhibitory rate of only 24.7% at the same dose. The above results indicate that (-)-PAN\u00b7Na is more potent than (+)-PAN\u00b7Na at inhibiting acid-related lesions owing to its stronger inhibition of acid secretion.<\/jats:p>","DOI":"10.1211\/0022357056361","type":"journal-article","created":{"date-parts":[[2005,6,14]],"date-time":"2005-06-14T01:33:05Z","timestamp":1118712785000},"page":"923-927","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs"],"prefix":"10.1093","volume":"57","author":[{"given":"Hong","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Shenyang Pharmaceutical University , Shenyang,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shenyang Pharmaceutical University , Shenyang,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Xin","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shenyang Pharmaceutical University , Shenyang,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ikejima","sequence":"additional","affiliation":[{"name":"China-Japan Research Institute of Medical and Pharmaceutical Sciences, Shenyang Pharmaceutical University , Shenyang,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Qing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Showa University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Hua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, Showa University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,7,1]]},"reference":[{"key":"2024103109413484400_cit1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2165\/00003088-200140060-00003","article-title":"Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole","volume":"40","author":"Andersson","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"2024103109413484400_cit2","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1046\/j.1365-2036.2001.01087.x","article-title":"Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole","volume":"15","author":"Andersson","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2024103109413484400_cit3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0014-2999(92)90178-7","article-title":"Pantoprazole: a novel H+\/K(+)-ATPase inhibitor with an improved pH stability","volume":"218","author":"Beil","year":"1992","journal-title":"Eur. J. Pharmacol."},{"key":"2024103109413484400_cit4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1523-5378.2003.00179.x","article-title":"Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies","volume":"8","author":"Bochenek","year":"2003","journal-title":"Helicobacter"},{"issue":"Suppl. 1","key":"2024103109413484400_cit5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2036.1994.tb00259.x","article-title":"Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment","volume":"8","author":"Brunner","year":"1994","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2024103109413484400_cit6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/jhs.50.1","article-title":"Comparison of the effects of pantoprazole enantiomers on gastric mucosal lesions and gastric epithelial cells in rats","volume":"50","author":"Cao","year":"2004","journal-title":"J. Health Sci."},{"key":"2024103109413484400_cit7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003495-200363010-00006","article-title":"Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders","volume":"63","author":"Cheer","year":"2003","journal-title":"Drugs"},{"key":"2024103109413484400_cit8","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/gut.32.12.1436","article-title":"Relations among autonomic nerve dysfunction, oesophageal motility, and gastric emptying in gastro-oesophageal reflux disease","volume":"32","author":"Cunningham","year":"1991","journal-title":"Gut"},{"key":"2024103109413484400_cit9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/clpt.1986.150","article-title":"Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview","volume":"40","author":"Drayer","year":"1986","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103109413484400_cit10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/path.1700900243","article-title":"Acute gastric ulceration in the guinea-pig induced by a single intraperitoneal injection of aqueous histamine","volume":"90","author":"Eagleton","year":"1965","journal-title":"J. Pathol. Bacteriol."},{"key":"2024103109413484400_cit11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2165\/00003495-199651030-00012","article-title":"Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders","volume":"51","author":"Fitton","year":"1996","journal-title":"Drugs"},{"issue":"Suppl","key":"2024103109413484400_cit12","doi-asserted-by":"crossref","first-page":"193P","DOI":"10.1016\/S0021-5198(19)56414-9","article-title":"Experimental model of acute esophagitis in the rat and comparison of effectiveness of antiulcer drugs including H2-antagonists and omeprazole","volume":"49","author":"Goto","year":"1989","journal-title":"Jpn. J. Pharmacol."},{"key":"2024103109413484400_cit13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s002280000206","article-title":"Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects","volume":"56","author":"Hassan-Alin","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2024103109413484400_cit14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2036.1995.tb00394.x","article-title":"Review article: the continuing development of proton pump inhibitors with particular reference to panto-prazole","volume":"9","author":"Huber","year":"1995","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2024103109413484400_cit15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1023\/A:1016062508580","article-title":"Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmaco-kinetics in humans","volume":"13","author":"Katsuki","year":"1996","journal-title":"Pharm. Res."},{"key":"2024103109413484400_cit16","first-page":"129","article-title":"BY 1023\/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions","volume":"254","author":"Kromer","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103109413484400_cit17","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1365-2036.2000.00813.x","article-title":"Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease","volume":"14","author":"Lind","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2024103109413484400_cit18","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1046\/j.1365-2036.2003.01560.x","article-title":"Helicobacter pylori eradication and gastric ulcer healing \u2014 comparison of three pantoprazole-based triple therapies","volume":"17","author":"Malfertheiner","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2024103109413484400_cit19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/(SICI)1520-636X(1998)10:8<747::AID-CHIR5>3.0.CO;2-B","article-title":"Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats","volume":"10","author":"Masubuchi","year":"1998","journal-title":"Chirality"},{"key":"2024103109413484400_cit20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/j.1552-4604.1992.tb04642.x","article-title":"Bioequivalence of racemic drugs","volume":"32","author":"Nerurkar","year":"1992","journal-title":"J. Clin. Pharmacol."},{"key":"2024103109413484400_cit21","first-page":"61","article-title":"Impairment of vagal function in reflux oesophagitis","volume":"54","author":"Ogilvie","year":"1985","journal-title":"Q. J. Med."},{"key":"2024103109413484400_cit22","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1046\/j.1365-2036.2003.01593.x","article-title":"Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole","volume":"17","author":"Pilotto","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2024103109413484400_cit23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00003495-199856030-00002","article-title":"Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders","volume":"56","author":"Richardson","year":"1998","journal-title":"Drugs"},{"key":"2024103109413484400_cit24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0006-2952(91)90722-H","article-title":"The H+, K(+)-ATPase inhibitor pantoprazole (BY1023\/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole","volume":"42","author":"Simon","year":"1991","journal-title":"Biochem. Pharmacol."},{"key":"2024103109413484400_cit25","first-page":"43","article-title":"A simple method for the uniform production of gastric ulceration in the rat","volume":"5","author":"Shay","year":"1945","journal-title":"Gastroenterology"},{"key":"2024103109413484400_cit26","first-page":"385","article-title":"Lack of pantoprazole drug interactions in man","volume":"32","author":"Steinijans","year":"1994","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"2024103109413484400_cit27","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1021\/ac951127n","article-title":"Direct determination of pantoprazole enantiomers in human serum by reversed-phase high-performance liquid chromatography using a cellulose-based chiral stationary phase and column-switching system as a sample cleanup procedure","volume":"68","author":"Tanaka","year":"1996","journal-title":"Anal. Chem."},{"key":"2024103109413484400_cit28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1520-636X(1997)9:1<17::AID-CHIR4>3.0.CO;2-D","article-title":"Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole \u2014 a preliminary study","volume":"9","author":"Tanaka","year":"1997","journal-title":"Chirality"},{"key":"2024103109413484400_cit29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1067\/mcp.2001.113723","article-title":"Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin","volume":"69","author":"Tanaka","year":"2001","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1211%2F0022357056361","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/57\/7\/923\/60261517\/0022357056361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/57\/7\/923\/60261517\/0022357056361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:24:42Z","timestamp":1730370282000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/57\/7\/923\/6147481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2005,7,1]]},"published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1211\/0022357056361","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"type":"print","value":"0022-3573"},{"type":"electronic","value":"2042-7158"}],"subject":[],"published-other":{"date-parts":[[2005,7]]},"published":{"date-parts":[[2005,7,1]]}}}